C.R. Franks - Concepedia

Author

C.R. Franks

Centre Léon Bérard

Also Known As

C Franks, C R Franks, C. Franks, C. R. FRANKS, C. R. Franks, C.R. Franks, Chris Franks, Chris R. Franks

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Hôpital Edouard Herriot National Institute for Biological Standards and Control Erasmus MC Cancer Institute St Bartholomew's Hospital

About

C.R. Franks is an author at Centre Léon Bérard specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	25	768
2	Cell Biology	4	4	89
3	Health Sciences	2	2	35
4	Public Health	1	1	32
5	Social Sciences	1	1	66

C.R. Franks

Publications

895

Citations

H-Index

Page 1

	Year	Citations
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Peter Palmer, J. Vinke, Thierry Philip, Annals of Oncology Prognostic FactorsUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	1992	156
Changes in Functional Brain Networks following Sports-Related Concussion in Adolescents Naznin Virji‐Babul, Courtney G. E. Hilderman, Nadia Makan, Journal of Neurotrauma NeuropsychologyHead InjuryBrain OrganizationLocal MetricsSocial Sciences	2014	66
Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer Rob L. H. Jansen, Rob Slingerland, S.H. Goey, Journal of Immunotherapy	1992	56
Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study Hans von der Maase, Poul Geertsen, Nicholas Thatcher, European Journal of Cancer and Clinical Oncology UrologyGenitourinary CancerKidney ResearchMedicineImmunology	1991	53
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed mice. E J Stanbredge, L.R. Boulger, C.R. Franks, PubMed Tumor BiologySuch SelectivityMalignant DiseaseImmunosuppressed MiceTumor Growth	1975	38
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot study Donald Macdonald, Yin‐Zheng Jiang, Andrea A. Gordon, Leukemia Research Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunologyRecombinant Interleukin 2	1990	36
Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients Thierry Philip, A. Mercatello, Sylvie Négrier, Cancer Treatment Reviews Lyon First-year ExperienceUrologyLak CellsGenitourinary CancerMalignant Disease	1989	34
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2 Hartmut Kirchner, Alfred Körfer, Pauline Evers, Cancer	1991	33
The effect of sex hormones on the growth of HeLa tumour nodules in male and female mice C.R. Franks, F. T. Perkins, D Bshop British Journal of Cancer InfertilityHormonal ReceptorSex HormonesHistopathologyGynecology	1975	32
The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2 J. G. M. Scharenberg, Anita G.M. Stam, B. Mary E. von Blomberg, European Journal of Cancer CytokineCancer ImmunosurveillanceAutoimmune DiseaseImmunologyImmunologic Mechanism	1994	28

Page 1